Aligos Therapeutics Inc (ALGS) - Net Assets
Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has net assets worth $53.55 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($89.58 Million) and total liabilities ($36.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aligos Therapeutics Inc (ALGS) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $53.55 Million |
| % of Total Assets | 59.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | -71.01% |
| 10-Year Change | N/A |
| Growth Volatility | 48.27 |
Aligos Therapeutics Inc - Net Assets Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore ALGS total asset value for the complete picture of this company's asset base.
Annual Net Assets for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual net assets of Aligos Therapeutics Inc from 2018 to 2025. For live valuation and market cap data, see ALGS company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $53.55 Million | +284.81% |
| 2024-12-31 | $-28.97 Million | -131.47% |
| 2023-12-31 | $92.08 Million | -11.38% |
| 2022-12-31 | $103.90 Million | -43.76% |
| 2021-12-31 | $184.73 Million | -16.05% |
| 2020-12-31 | $220.04 Million | +439.09% |
| 2019-12-31 | $-64.89 Million | -372.00% |
| 2018-12-31 | $-13.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aligos Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 62826800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.02% |
| Other Comprehensive Income | $468.00K | 0.87% |
| Other Components | $695.27 Million | 1298.48% |
| Total Equity | $53.55 Million | 100.00% |
Aligos Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Aligos Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NextCure Inc
NASDAQ:NXTC
|
$32.81 Million |
|
NXT Energy Solutions Inc
TO:SFD
|
$32.82 Million |
|
KCP Sugar and Industries Corporation Limited
NSE:KCPSUGIND
|
$32.83 Million |
|
Tong-Hwa Synthetic Fiber Co Ltd
TW:1418
|
$32.85 Million |
|
Seoyon Topmetal Co. Ltd
KQ:019770
|
$32.80 Million |
|
Biotoxtech Co. Ltd
KQ:086040
|
$32.80 Million |
|
OnKure Therapeutics, Inc.
NASDAQ:OKUR
|
$32.79 Million |
|
Ma Kuang Healthcare Holding Ltd
TWO:4139
|
$32.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aligos Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -28,973,000 to 53,545,000, a change of 82,518,000.
- Net loss of 24,193,000 reduced equity.
- New share issuances of 101,345,000 increased equity.
- Other comprehensive income increased equity by 17,000.
- Other factors increased equity by 5,349,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.19 Million | -45.18% |
| Share Issuances | $101.34 Million | +189.27% |
| Other Comprehensive Income | $17.00K | +0.03% |
| Other Changes | $5.35 Million | +9.99% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aligos Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.12x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.65 | $6.09 | x |
| 2019-12-31 | $-2.96 | $6.09 | x |
| 2020-12-31 | $6.44 | $6.09 | x |
| 2021-12-31 | $4.64 | $6.09 | x |
| 2022-12-31 | $2.43 | $6.09 | x |
| 2023-12-31 | $3.70 | $6.09 | x |
| 2024-12-31 | $-4.62 | $6.09 | x |
| 2025-12-31 | $5.42 | $6.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aligos Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1106.72%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.65x
- Recent ROE (-45.18%) is below the historical average (-43.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.56 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-45.77 Million |
| 2020 | -49.33% | 0.00% | -0.04x | 1.21x | $-130.55 Million |
| 2021 | -69.47% | -2944.07% | 0.02x | 1.27x | $-146.81 Million |
| 2022 | -92.44% | -690.63% | 0.09x | 1.41x | $-106.44 Million |
| 2023 | -95.22% | -564.61% | 0.10x | 1.65x | $-96.89 Million |
| 2024 | 0.00% | -3326.01% | 0.06x | 0.00x | $-128.31 Million |
| 2025 | -45.18% | -1106.72% | 0.02x | 1.65x | $-29.55 Million |
Industry Comparison
This section compares Aligos Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aligos Therapeutics Inc (ALGS) | $53.55 Million | 0.00% | 0.67x | $32.81 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more